Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124192600> ?p ?o ?g. }
- W2124192600 endingPage "520" @default.
- W2124192600 startingPage "520" @default.
- W2124192600 abstract "To study the safety and efficacy of pegylated interferon alfa-2b, indigenously developed in India, plus ribavirin in treatment of hepatitis C virus (HCV).One-hundred HCV patients were enrolled in an open-label, multicenter trial. Patients were treated with pegylated interferon alfa-2b 1.5 μg/kg per week subcutaneously plus oral ribavirin 800 mg/d for patients with genotypes 2 and 3 for 24 wk. The same dose of peginterferon plus weight-based ribavirin (800 mg/d for ≤ 65 kg; 1000 mg/d for > 65-85 kg; 1200 mg/d for > 85-105 kg; 1400 mg/d for > 105 kg body weight) was administered for 48 wk for patients with genotypes 1 and 4. Serological and biochemical responses of patients were assessed.Eighty-two patients (35 in genotypes 1 and 4 and 47 in 2 and 3), completed the study. In genotype 1, 25.9% of patients achieved rapid virologic response (RVR): while the figures were 74.1% for early virologic response (EVR) and 44.4% for sustained virologic response (SVR). For genotypes 2 and 3, all patients bar one belonged to genotype 3, and of those, 71.4%, 87.5%, and 64.3% achieved RVR, EVR, and SVR, respectively. In genotype 4, 58.8%, 88.2%, and 52.9% of patients achieved RVR, EVR, and SVR, respectively. The majority of patients attained normal levels of alanine aminotransferase by 4-12 wk of therapy. Most patients showed a good tolerance for the treatment, although mild-to-moderate adverse events were exhibited; only two patients discontinued the study medication due to serious adverse events (SAEs). Eleven SAEs were observed in nine patients; however, only four SAEs were related to study medication.Peginterferon alfa-2b, which was developed in India, in combination with ribavirin, is a safe and effective drug in the treatment of HCV." @default.
- W2124192600 created "2016-06-24" @default.
- W2124192600 creator A5002482699 @default.
- W2124192600 creator A5032381244 @default.
- W2124192600 creator A5035638598 @default.
- W2124192600 creator A5046367184 @default.
- W2124192600 creator A5051866002 @default.
- W2124192600 creator A5058416607 @default.
- W2124192600 creator A5058627455 @default.
- W2124192600 creator A5058918705 @default.
- W2124192600 creator A5059721150 @default.
- W2124192600 creator A5061522756 @default.
- W2124192600 creator A5076057471 @default.
- W2124192600 date "2014-01-01" @default.
- W2124192600 modified "2023-09-24" @default.
- W2124192600 title "Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C" @default.
- W2124192600 cites W139093517 @default.
- W2124192600 cites W1521422221 @default.
- W2124192600 cites W1965697359 @default.
- W2124192600 cites W1977076145 @default.
- W2124192600 cites W1980390916 @default.
- W2124192600 cites W1981588917 @default.
- W2124192600 cites W1992239172 @default.
- W2124192600 cites W1996062178 @default.
- W2124192600 cites W2007648965 @default.
- W2124192600 cites W2017972113 @default.
- W2124192600 cites W2018774166 @default.
- W2124192600 cites W2024043429 @default.
- W2124192600 cites W2034654277 @default.
- W2124192600 cites W2065986600 @default.
- W2124192600 cites W2095545746 @default.
- W2124192600 cites W2112876622 @default.
- W2124192600 cites W2113864802 @default.
- W2124192600 cites W2127685726 @default.
- W2124192600 cites W2156857913 @default.
- W2124192600 cites W2157961528 @default.
- W2124192600 cites W2161057754 @default.
- W2124192600 cites W2327525734 @default.
- W2124192600 cites W2792087431 @default.
- W2124192600 cites W3121676111 @default.
- W2124192600 cites W4211077792 @default.
- W2124192600 doi "https://doi.org/10.4254/wjh.v6.i7.520" @default.
- W2124192600 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4110544" @default.
- W2124192600 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25068004" @default.
- W2124192600 hasPublicationYear "2014" @default.
- W2124192600 type Work @default.
- W2124192600 sameAs 2124192600 @default.
- W2124192600 citedByCount "5" @default.
- W2124192600 countsByYear W21241926002015 @default.
- W2124192600 countsByYear W21241926002019 @default.
- W2124192600 countsByYear W21241926002021 @default.
- W2124192600 crossrefType "journal-article" @default.
- W2124192600 hasAuthorship W2124192600A5002482699 @default.
- W2124192600 hasAuthorship W2124192600A5032381244 @default.
- W2124192600 hasAuthorship W2124192600A5035638598 @default.
- W2124192600 hasAuthorship W2124192600A5046367184 @default.
- W2124192600 hasAuthorship W2124192600A5051866002 @default.
- W2124192600 hasAuthorship W2124192600A5058416607 @default.
- W2124192600 hasAuthorship W2124192600A5058627455 @default.
- W2124192600 hasAuthorship W2124192600A5058918705 @default.
- W2124192600 hasAuthorship W2124192600A5059721150 @default.
- W2124192600 hasAuthorship W2124192600A5061522756 @default.
- W2124192600 hasAuthorship W2124192600A5076057471 @default.
- W2124192600 hasBestOaLocation W21241926001 @default.
- W2124192600 hasConcept C126322002 @default.
- W2124192600 hasConcept C197934379 @default.
- W2124192600 hasConcept C203014093 @default.
- W2124192600 hasConcept C2522874641 @default.
- W2124192600 hasConcept C2776408679 @default.
- W2124192600 hasConcept C2776455275 @default.
- W2124192600 hasConcept C2776461080 @default.
- W2124192600 hasConcept C2780040827 @default.
- W2124192600 hasConcept C71924100 @default.
- W2124192600 hasConcept C90924648 @default.
- W2124192600 hasConceptScore W2124192600C126322002 @default.
- W2124192600 hasConceptScore W2124192600C197934379 @default.
- W2124192600 hasConceptScore W2124192600C203014093 @default.
- W2124192600 hasConceptScore W2124192600C2522874641 @default.
- W2124192600 hasConceptScore W2124192600C2776408679 @default.
- W2124192600 hasConceptScore W2124192600C2776455275 @default.
- W2124192600 hasConceptScore W2124192600C2776461080 @default.
- W2124192600 hasConceptScore W2124192600C2780040827 @default.
- W2124192600 hasConceptScore W2124192600C71924100 @default.
- W2124192600 hasConceptScore W2124192600C90924648 @default.
- W2124192600 hasIssue "7" @default.
- W2124192600 hasLocation W21241926001 @default.
- W2124192600 hasLocation W21241926002 @default.
- W2124192600 hasLocation W21241926003 @default.
- W2124192600 hasLocation W21241926004 @default.
- W2124192600 hasOpenAccess W2124192600 @default.
- W2124192600 hasPrimaryLocation W21241926001 @default.
- W2124192600 hasRelatedWork W1586448152 @default.
- W2124192600 hasRelatedWork W180129732 @default.
- W2124192600 hasRelatedWork W1929853255 @default.
- W2124192600 hasRelatedWork W2033989269 @default.
- W2124192600 hasRelatedWork W2059421866 @default.
- W2124192600 hasRelatedWork W2082200384 @default.
- W2124192600 hasRelatedWork W2083588500 @default.